Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | GCG | P01275 | 1/20 | 0.48 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961842 | 0.87 | PTGS1 (0.59) | PTGDR2AKR1B1KMT2APTGER1PTGER4 | |
| SCHEMBL538512 | 0.87 | KMT2A (0.60) | PTGDR2FFAR4FFAR1AKR1B1KMT2A | |
| SCHEMBL7598404 | 0.86 | CYP2C19 (0.54) | SUCNR1PTGDR2CYP2C19FFAR4FFAR1 | |
| Ammonia Solution, Strong SCHEMBL27926479 | 0.85 | KMT2A (0.58) | PTGDR2FFAR4FFAR1AKR1B1KMT2A | |
| SCHEMBL8645744 | 0.85 | PTGS1 (0.55) | PTGDR2AKR1B1KMT2APTGER1PTGER4 | |
| SCHEMBL28594606 | 0.85 | KMT2A (0.58) | PTGDR2FFAR4FFAR1AKR1B1KMT2A | |
| SCHEMBL27701716 | 0.85 | KMT2A (0.58) | PTGDR2FFAR4FFAR1KDM4EAKR1B1 | |
| Hydrochloric Acid SCHEMBL11895689 | 0.85 | KMT2A (0.58) | PTGDR2FFAR4FFAR1AKR1B1KMT2A | |
| SCHEMBL29512995 | 0.85 | KMT2A (0.58) | PTGDR2FFAR4FFAR1AKR1B1KMT2A | |
| SCHEMBL13802493 | 0.84 | PTGER1 (0.49) | SUCNR1PTGDR2AKR1B1CXCL8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746142-A | Method for synthesis of 2-(2-(4-chlorphenyl)phenyl)acetic acid | SHENGSHI TAIKE BIOLOG MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-24 | — | — | CN | claimed |
| CN-102746209-A | A synthetic method for 3-(2-(4-chlorophenoxy)phenyl )-1-methyl-2,4-dione | SHENGSHI TAIKE BIOLOG MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-24 | — | — | CN | claimed |
| CN-102791693-B | Hepatitis c virus inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2016-04-13 | — | — | CN | disclosed |
| WO-2015042405-A1 | PH SWITCHABLE REAGENTS AND METHODS FOR THEIR USE | IMPOSSIBLE FOODS INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-1817031-B1 | CASPASE-10 INHIBITORS FOR PREVENTION AND TREATMENT OF RETINOPATHY | MERCK PATENT GMBH (DE) | 2014-05-21 | — | — | EP | disclosed |
| CN-102746142-A | Method for synthesis of 2-(2-(4-chlorphenyl)phenyl)acetic acid | SHENGSHI TAIKE BIOLOG MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-24 | — | — | CN | disclosed |
| CN-102746142-A | Method for synthesis of 2-(2-(4-chlorphenyl)phenyl)acetic acid | SHENGSHI TAIKE BIOLOG MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-24 | — | — | CN | disclosed |
| CN-102746142-A | Method for synthesis of 2-(2-(4-chlorphenyl)phenyl)acetic acid | SHENGSHI TAIKE BIOLOG MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-24 | — | — | CN | disclosed |
| CN-102746209-A | A synthetic method for 3-(2-(4-chlorophenoxy)phenyl )-1-methyl-2,4-dione | SHENGSHI TAIKE BIOLOG MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-24 | — | — | CN | disclosed |
| CN-102746209-A | A synthetic method for 3-(2-(4-chlorophenoxy)phenyl )-1-methyl-2,4-dione | SHENGSHI TAIKE BIOLOG MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-10-24 | — | — | CN | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-7727990-B2 | Melanocortin receptor-specific piperazine and keto-piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1919479-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | Palatin Technologies, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007021991-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SUCNR1 1789/4885PTGDR2 1062/4885CYP2C19 240/4885 |
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP5 | SUCNR1 3164/4885PTGDR2 3995/4885CYP2C19 2904/4885 |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | MC4R, MC5R, MC1R | SUCNR1 606/4885PTGDR2 198/4885CYP2C19 2624/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | SUCNR1 4180/4885PTGDR2 2287/4885CYP2C19 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.